Compare Quest Diagnostics Inc (DGX) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kaltura Inc — how do they compare? Quest Diagnostics Inc trades at $237.54 (market cap $26.21B), while Kaltura Inc trades at $1.58 (market cap $249.42M). The key difference: Quest Diagnostics Inc is far larger — about 105.1× Kaltura Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.
| DGX | KLTR | |
|---|---|---|
Market Cap | $26.21B | $249.42M |
Sector | Health | Technology |
52-Week High | $238.50 | $1.89 |
52-Week Low | $173.49 | $1.08 |
Enterprise Value | $31.97B | $261.64M |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
KLTR trades at $1.59, down 3.05% today, with a bullish technical signal from moving averages and strong institutional recognition for its AI-driven digital experience platform. Revenue is stable around $181M annually, but the company remains unprofitable, with a net income margin of -6.92% in 2026. Recent earnings beats and multiple industry awards highlight operational progress amid high valuation multiples like EV/EBITDA of 336.29.
The outlook is cautiously optimistic due to consistent revenue and margin improvements, but persistent losses and high debt pose risks. Analyst sentiment is mixed with a 44.45% buy rating, suggesting potential upside if profitability is achieved, though investor caution is warranted given the negative cash flow and insider selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
